Pulmonary-Affinity Paclitaxel Polymer Micelles in Response to Biological Functions of Ambroxol Enhance Therapeutic Effect on Lung Cancer.

Abstract

PURPOSE:

Cancer chemotherapy effect has been largely limited by cell autophagy and little drug accumulation at the action sites. Herein, we designed an intelligent strategy involving paclitaxel (PTX) polymer micelles in response to biological functions of ambroxol (Ax). The amphiphilic polymers polyethyleneglycol-polylactic acid (PEG-PLA) and Pluronic P105 were selected as nanocarriers to encapsulate PTX to form into lung affinity PEG-PLA/P105/PTX micelles. Ax which can up-regulate the secretion of pulmonary surfactant (PS) and inhibit autophagy was hired to change the microenvironment of the lung, thereby promoting the lung accumulation and increasing cell-killing sensitivity of the micelles.

METHODS:

The physical and chemical properties of the micelles were characterized including size, morphology, critical micellar concentration (CMC) and in vitro drug release behavior. The therapeutic effects of the combination regimen were characterized both in vitro and in vivo including study on Ax in promoting the secretion of pulmonary surfactant, in vitro cytotoxicity, cellular uptake, Western blotting, in vivo biodistribution, in vivo pharmacokinetics and in vivo antitumor efficacy.

RESULTS:

The PEG-PLA/P105/PTX micelles showed a particle size of 16.7 ± 0.5 nm, a nearly round shape, small CMC and sustained drug release property. Moreover, the in vitro results indicated that Ax could increase PS and LC3 protein secretion and enhance the cytotoxicity of PEG-PLA/P105/PTX micelles toward A549 cells. The in vivo results indicated that the combination therapeutic regimen could promote the micelles to distribute in lung and enhance the therapeutic effect on lung cancer.

CONCLUSION:

This multifunctional approach of modulating the tumor microenvironment to enhance drug transportation and cell-killing sensitivity in the action sites might offer a new avenue for effective lung cancer treatment.

• Authors: Wenxiu He, Wenze Xiao, Xiulei Zhang, Yali Sun, Yiting Chen, Qinyue Chen, Xiaoling Fang, Shilin Du, Xianyi Sha
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 15 Pg. 779-793 ( 2020) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 32099365 (Publication Type: Journal Article)
• Copyright: © 2020 He et al.

Chemical References

• Delayed-Action Preparations
• Drug Carriers
• Micelles
• Polymers
• monomethoxypolyethyleneglycol-polylactide block copolymer
• Poloxamer
• Ambroxol
• Polyethylene Glycols
• pluronic P105
• Paclitaxel

Topics

• Ambroxol (administration & dosage)
• Animals
• Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics, pharmacology)
• Delayed-Action Preparations (therapeutic use)
• Drug Carriers (chemistry, pharmacokinetics)
• Drug Liberation
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Mice, Inbred BALB C
• Mice, Inbred ICR
• Micelles
• Paclitaxel (administration & dosage, pharmacology)
• Particle Size
• Poloxamer (chemistry)
• Polyethylene Glycols (chemistry)
• Polymers (chemistry)
• Rats, Sprague-Dawley
• Tissue Distribution